New York State Stands by its 340B-Related Antitrust Claims Against CVS

CVS retail building
New York State last week reasserted claims that CVS Health illegally forces 340B providers to use its 340B TPA Wellpartner.

The New York State attorney general last week reasserted that CVS Health abused its market power by forcing 340B covered entities who use CVS to dispense 340B-priced drugs to use the retail chain’s third-party administrator Wellpartner to process their 340B

Read More »
Industry Insights Logo

Your Guide to Navigating 340B ESP

Larry Crowder headshot

SPONSORED CONTENT

The 340B ESP price loading process can be complex. If you’re a covered entity who contracts with outside pharmacies, here’s your guide to navigating 340B ESP, starting with the basics. Equip yourself with these tips to troubleshoot any price loading roadblocks you may encounter, and ensure pricing is loaded

Read More »

Feds in Mediation with Tenn. Health System that Allegedly Paid for Referrals to Boost 340B Profits

Methodist Le Bonheur Healthcare building
Methodist Le Bonheur Healthcare and the federal government have settled a 340B-related False Claims Act suit against the system.

The federal government and a Tennessee health system are meeting with a mediator in connection with a whistleblower lawsuit that alleges that the system paid Memphis-area cancer physicians for referrals that generated $50 million in profits in one year alone

Read More »

Breaking News

In Key Hearing, Appeals Court Panel Seems to Lean in Favor of Some Drug Manufacturer Conditions on 340B Pricing

CADC courtroom
A federal appeals court in Washington, D.C., heard arguments this morning in Novartis and United Therapeutics' consolidated 340B contract pharmacy cases.

Two of three judges on a federal appeals court panel strongly indicated this morning that they reject the federal government’s position that nothing in the 340B statute gives drug manufacturers the right to put any conditions on offers of 340B

Read More »

Breaking News

HRSA Refers Merck to HHS Inspector General Over its 340B Contract Pharmacy Policy

Merck flag with U.S. flag
Merck did not immediately comment on the governnment's referral yesterday to the HHS Inspector General for possible imposition of civil fines over the company's 340B contract pharmacy restrictions.

The U.S. Health Resources and Services Administration yesterday referred drug manufacturer Merck to the Department of Health and Human Services Office of Inspector General for possible imposition of civil fines over Merck’s 340B contract pharmacy restrictions.

Public Health Services Lt.

Read More »

CMS Says Steps to End Medicare Drug Payment Cut for 340B Hospitals Are in Progress

CMS building
CMS says it is making computer file changes to restore hospitals’ Part B payments for 340B-purchased drugs to average sales price plus 6% for the rest of 2022 after paying them almost 30% less since 2018.

The U.S. Centers for Medicare & Medicaid Services is making computer file changes to restore hospitals’ Part B payments for 340B-purchased drugs to average sales price plus 6% for the rest of 2022 after paying them almost 30% less since

Read More »

340B COVID-19 Flexibilities Will Continue Through Mid-January

Screenshot of HRSA COVID-19, 340B program resources page
HHS extended the COVID-19 public health emergency (PHE) to mid-January, which keeps in place 340B program flexibilities that started in March 2020.

The U.S. Department of Health and Human Services (HHS) late last week extended the COVID-19 public health emergency (PHE) to mid-January, giving some 340B-eligible entities more time for immediate enrollment in the program without having to wait for the next

Read More »

Kalderos Announces New 340B Drug Claims Verification Tool

Kalderos Discount Hub logo
Kalderos has replaced its Review 340B claims verification tool with a new one named Discount Hub.

Pharmaceutical manufacturer contractor Kalderos has replaced Review, its 340B drug claims verification tool, with a new one named Discount Hub.

Chicago-based Kalderos announced the change in an Aug. 31 blog post and an Oct. 12 news release. It said Discount Hub

Read More »

NACHC Seeks Meeting with Becerra About 340B Contract Pharmacy Restrictions After “Inexplicable” ADR Decision

NACHC wordmark
NACHC told HHS Secretary Becerra it has “little choice” but to turn to Congress after an HHS panel dismissed NACHC’s 340B overcharging claims against AstraZeneca and Sanofi.

The National Association of Community Health Centers is asking to meet with U.S. Health and Human Services Secretary Xavier Becerra to discuss drug companies’ “unlawful restrictions” on 340B drug shipments to contract pharmacies.

NACHC told Becerra in an Oct. 14

Read More »

HRSA Tells AbbVie and Amgen Their 340B Contract Pharmacy Restrictions Are Illegal

HHS HRSA building entrance and signage
HRSA sent AbbVie and Amgen letters yesterday telling the companies their restrictions on 340B pricing when providers use contract pharmacies are illegal and must stop or the companies could face stiff civil monetary penalties.

Federal health officials told drug manufacturers AbbVie and Amgen late yesterday their restrictions on 340B pricing when providers use contract pharmacies are illegal and must end or the companies could be fined.

The Health Resources and Services Administration’s last 340B

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live